Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 3Completed 2Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × defactinib × Thoracic × Clear all
NCT04620330 2024-01-12

RAMP202

Verastem, Inc.

Phase 2 Completed
90 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01951690 2017-04-13

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Verastem, Inc.

Phase 2 Completed
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡